## **TAALERI**

08/13/2025 20.45 EEST

This is a translated version of the "Raportissa ei yllätyksiä, fokus jo tulevassa CMD:ssä" report, published on 08/13/2025



Sauli Vilén +358440258908 sauli.vilen@inderes.fi

**INDERES CORPORATE CUSTOMER** 

# **COMPANY REPORT**



### No surprises in the report, focus on the upcoming CMD

We reiterate our EUR 9.0 target price and Buy recommendation for Taaleri. The Q2 report was in line with expectations, but the focus is already firmly on the upcoming strategy update. The stock continues to trade at a hefty discount relative to its sum of the parts, and it is also cheap in absolute terms. The key question is how to highlight the undeniable value of the parts. We hope to get a clear answer to this question at the fall's CMD, because without a clear roadmap for unlocking value, a price below the sum of the parts is justified.

#### **Q2** report in line with expectations

Taaleri's Q2 report was well in line with our expectations, and a marginal earnings miss is explained by the effects of the dollar on the investment portfolio. Operationally, the quarter was better than we expected, as Garantia seems to be turning back to growth. We commented on Taaleri's Wednesday result in more detail here.

As expected, there was no concrete information regarding the strategy yet, and the company will arrange a CMD on September 2. Our view remains that the value of the company's parts is not reflected in the current group structure.

### Big picture for estimates unchanged, capital allocation still a question mark

We have once again made many revisions to our estimates. For 2025, the biggest change is the postponement of the exit from old wind funds to 2026. For 2026-2027, our estimates for Garantia have risen slightly, as the company appears to be achieving growth faster than we expected.

2025 earnings are rather weak in our forecasts, as very little non-recurring income will materialize. Similarly, 2026 will be very strong, as several significant exits are expected to occur then.

As a whole, we predict that Taaleri's operating result will be 30 MEUR on average in the coming years. Earnings fluctuate

significantly on an annual level due to the significant weight of investment operations in the group's earnings. We expect the profitability of private equity funds to gradually improve along with the growth in AUM, but the timing and amount of nonrecurring fees will sway annual earnings somewhat. We expect Garantia to return to stable growth as the housing market slowly picks up. Bioindustry investments are a significant variable in the company's investment case and the schedule and magnitude of these are a key question mark in the CMD.

Our dividend forecasts remain cautious, as the focus of capital allocation is on investments.

### There is value in parts, but the route to materialize it is missing

In this analysis, we focus on the sum of the parts, as it is the best way to consider the value of different parts of Taaleri and the different profiles of the businesses. The value based on our conservative sum of the parts is around EUR 10 per share, which is clearly above the current share price level. The majority of the value is still generated by the insurance company Garantia. while the remainder is effectively split between the energy fund business and balance sheet investments. In absolute terms, the stock is also cheap. We think it is clear that there is significant value in the parts, but the route to materialize it and the timetable are question marks. We hope to get clear answers to this in the CMD this fall. If the company continues with its current structure and own-balance-sheet bioindustry investments are at the core of the strategy, we find it justified that the stock is priced below the sum of the parts. This is because the schedule for bioindustry investments is really long (the potential would be realized at the end of the decade at the earliest), and we also do not see the value of the different parts being fully realized in the current conglomerate-like structure.

### Recommendation

Buy

(was Buy)

### **Target price:**

**EUR 9.00** 

(was EUR 9.00)

### **Share price:**

EUR 7.12

#### **Business risk**







#### Valuation risk







	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e
Revenue	72.6	53.6	63.4	64.7
growth-%	11%	-26%	18%	2%
EBIT adj.	38.1	19.2	34.5	31.6
EBIT-% adj.	52.4 %	35.9 %	54.5 %	48.9 %
Net Income	28.0	11.6	25.9	23.7
EPS (adj.)	0.99	0.41	0.91	0.82
P/E (adj.)	8.1	17.5	7.8	8.6
P/B	1.1	1.0	0.9	0.9
Dividend yield-%	6.2 %	3.4 %	7.6 %	6.9 %
EV/EBIT (adj.)	6.0	9.5	4.9	5.8
EV/EBITDA	5.8	9.1	4.9	5.8
EV/S	3.1	3.4	2.7	2.8


Source: Inderes

### Guidance


No guidance

### **Share price** 14.0 13.0 12.0 11.0 10.0 9.0 8.0 7.0 6.0 8/22 8/23 8/24 OMXHCAP Taaleri Source: Millistream Market Data AB

### **Revenue and EBIT-% (adj.)**



### **EPS** and dividend



### **Value drivers**

- Scaling of Energia
- Ramping up Other private equity funds
- Garantia's profitable growth
- Balance sheet bioindustry investments
- M&A transactions
- Performance fees for funds

### **Risk factors**

- Success in fund investments
- Success of bioindustry investments
- Success of ramping up Other private equity funds
- Scalability of costs and improving costefficiency
- Garantia's guarantee risks

/aluation	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e
Share price	7.20	7.20	7.20
lumber of shares, millions	28.4	28.6	28.8
/larket cap	204	206	207
V	207	173	186
P/E (adj.)	17.7	7.9	8.7
P/E	17.7	7.9	8.7
Р/В	1.0	0.9	0.9
P/S	3.8	3.2	3.2
V/Sales	3.9	2.7	2.9
V/EBITDA	10.2	5.0	5.8
EV/EBIT (adj.)	10.8	5.0	5.9
Payout ratio (%)	60.0 %	60.0 %	60.0 %
Dividend yield-%	3.4 %	7.6 %	6.9 %

### **Report was in line with expectations**

### No major earnings surprises

Taaleri's EBIT was 4.5 MEUR, in line with our forecast of 5.0 MEUR. The weakened dollar weighed on the group's investment portfolio value by around one million, and adjusted for this, earnings would have been 5.5 MEUR. The tax rate was exceptionally high in Q2, which pushed EPS clearly below our estimate.

### The fundraising of the SolarWind3 fund progressed

Regarding renewable energy, the SolarWind3 fund's fundraising progressed and the fund's size increased to 503 MEUR (Q1'25: 481 MEUR). The fund is still open to one new investor until the end of the year. It is clear that this is a significant investor, and any potential subscription would inevitably be tens of millions of euros. Fees from Renewable Energy were somewhat higher than we expected, as the fund grew more than expected, and significant management fees were retroactively recorded

from this. There were no surprises in Renewable Energy costs and profitability scaled well with growth. There were no surprises in the figures for other private equity funds.

### **Garantia performed strongly**

Garantia again continued its strong operational performance. Garantia's insurance premium income grew contrary to our expectations by 3% to 4.9 MEUR, and the guarantee insurance portfolio also turned to slight growth due to the pick-up in mortgage demand. The loss ratio was slightly higher (19.9%) for the first time in a while and this weighed on the insurance service result. Despite minor damages, the combined ratio was still strong at 51%. We are not concerned about the increase in compensation, and expect the normal level to be clearly lower than the Q2 level. Garantia's investment portfolio return was strong in line with our expectations thanks to the good momentum of the capital market.

#### Exits from old wind funds are postponed

No changes occurred in Taaleri's own investment portfolio during the review period, but the decline of the dollar pushed the investment portfolio's return more than one million into the red. Group expenses were slightly higher than our expectations, and we consider it possible that they include strategy-related costs.

Taaleri made a small revision to its outlook, as it now expects the exit from older wind funds to likely happen only after 2025. We had previously expected the exit in 2025, and the delay is a little disappointing to us. We note that although the exit market is undeniably gloomy, the continuously prolonged exit process increases the risk to the fund's future performance fees. Regarding already recognized performance fees, management stated in our interview that they are tested quarterly, and we are not particularly concerned about these. As expected, the new strategy was not yet mentioned in the earnings release.

Estimates	Q2'24	Q2'25	Q2'25e	Q2'25e	Consensus	Difference (%)	<b>2025</b> e
MEUR / EUR	Comparison	Actualized	Inderes	Consensus	Low High	Act. vs. inderes	Inderes
Revenue	12.6	12.9	13.4			-4%	53.6
EBIT (adj.)	4.4	4.5	5.0			-10%	19.2
EPS (adj.)	0.11	0.07	0.10			-30%	0.41
Revenue growth-%	-46.9 %	2.1 %	6.0 %			-4 pp	-26.1 %
EBIT-% (adj.)	34.7 %	34.9 %	37.3 %			-2.4 pp	35.9 %

### **Estimates unchanged in the big picture**

#### **Estimate revisions**

Source: Inderes

- We have once again made many revisions to our estimates. For 2025, the biggest change is the postponement of the exit from old wind funds to 2026.
- For 2026-2027, our estimates for Garantia have risen slightly, as the company appears to be achieving growth faster than we expected. We have slightly revised our revenue estimates down in Renewable Energy as the SolarWind3 fund fell a bit short of our estimates. The segment's cost structure has, however, improved beyond our expectations in recent quarters, and the impact of lower cost estimates outweighs the impact of the lower revenue estimate.
- We have adopted a slightly more cautious stance on the returns from bioindustry investments in investment operations.
- Our dividend forecasts remain cautious, as the focus of capital allocation is on investments. In our interview, the company's management once again spoke surprisingly openly about the company's interest in M&A deals in the industry, and based on the comments, we find it possible that the company itself will be an active party in M&A deals. From a capital allocation perspective, this would also be logical, as the large investments in bioindustry that were previously discussed seem to be significantly smaller than planned. In addition, the company's balance sheet is very strong and enables medium-sized deals without using own shares.

Estimate revisions MEUR / EUR	2025e Old	2025e New	Change %	2026e Old	2026e New	Change %	2027e Old	2027e New	Change %
Revenue	56.6	53.6	-5%	61.2	63.4	4%	66.4	64.7	-3%
Private equity funds	34.3	31.2	-9%	35.7	38.1	7%	35.6	34.5	-3%
Garantia	16.9	17.2	2%	19.8	21.1	6%	20.5	21.8	6%
Others	1.2	1.3	7%	1.5	1.5	0%	1.5	1.5	0%
Investments (from 2024)	4.2	2.7	-36%	4.2	2.7	-36%	8.8	7.0	-21%
EBIT	23.0	19.2	<b>-17</b> %	28.2	34.5	<b>22</b> %	30.9	31.6	<b>2</b> %
Private equity funds	11.0	8.6	-21%	11.7	17.0	45%	10.8	12.3	15%
Garantia	15.9	16.3	3%	18.7	20.0	7%	19.3	20.6	7%
Others	-7.3	-7.4	-2%	-6.8	-6.9	-2%	-7.1	-7.2	-2%
Investments (from 2024)	3.4	1.7	-51%	4.6	4.5	-2%	7.9	5.9	-25%
PTP	22.6	18.9	-17%	27.9	34.2	23%	30.6	31.3	2%
EPS (adjusted)	0.51	0.41	<b>-21</b> %	0.73	0.91	24%	0.81	0.82	<b>2</b> %
Dividend / share	0.31	0.24	-21%	0.44	0.54	24%	0.49	0.49	2%

#### **Operational earnings drivers**

- o In Renewable Energy, earnings based on recurring fees have taken a clear leap forward with the latest SolarWind 3 fund, and profitability is already at a good level with recurring fees. The next level increase in profitability will occur in 2027 when the SolarWind4 fund makes its first exit. We also expect significant performance fees from the segment in the coming years from old wind funds and the Aurinkotuuli 1 fund. The segment's earnings outlook for the coming years is good.
- The recurring fee-based profitability from other private equity funds remains weak in our estimates, but turns profitable starting next year. Higher profitability requires significant growth in operations.
- We note that as a result of the reporting reform that came into effect at the beginning of the year, group expenses are higher than before, and correspondingly, the earnings of operating segments are better than before.
- Garantia's guarantee insurance business continues to perform steadily in our forecasts as the mortgage market gradually recovers.
- Overall, we expect the company to achieve earnings of some 30 MEUR in the next few years. However, the earnings level will especially in the long term be highly dependent on the company's balance sheet investments and capital allocation. We expect the company to clarify its capital allocation playbook in the CMD on September 2.

### Taaleri Half year financial report January-June 2025



### The sum of the parts has significant value

#### Sum of the parts as a basis for valuation

Since the profiles of Taaleri's different parts are very different, the sum of the parts serves as the best valuation method. However, we note that based on the latest strategy update, the value of the sum of the parts cannot be assumed to be unwound through various arrangements but must be derived from the cash flows of the businesses. Our estimate for Taaler's sum-of-the-parts value is roughly unchanged at around 279 MEUR (was 277 MEUR), which means approximately EUR 10 per share.

### **Share price under the SOTP value**

In our calculations, the current value of Taaleri consists of Garantia (170 MEUR, based on DDM), Renewable Energy (95 MEUR, based on peer calculation), balance sheet investment assets (72 MEUR, including performance fee receivables from old wind funds and investment tax liabilities), net cash (16 MEUR) and group expenses (-86 MEUR). The value contribution of Other private asset management is marginal (12 MEUR), as the business remains loss-making in our forecasts and profitability requires considerable success in new sales. Iln our view, our SOTP calculation is quite conservative and even with very small changes, the value could be EUR 1-2/share higher. It is therefore clear that there is significant value in the parts of the company, and the stock is priced well below this level. Also, in absolute terms, the stock is valued at low multiples, and this supports our view of cheap pricing. The P/B ratio has fallen to around 1x, which is difficult to consider justified.

### Thoughts on the future strategy

The key question (and challenge) related to Taaleri is how the value embedded in the company's parts can be unlocked. The single most important question about the future strategy update is the company structure. Will the company continue with its current structure, or will value be sought to be unlocked, for example, through a demerger? We believe it is clear that, e.g., with a demerger, significant value would be unlocked immediately, as the value of the parts would become apparent. If the company were to decide to dismantle its current structure by spinning off Garantia, it would simultaneously end the current bioindustry investment strategy, as Private equity funds would not have the capacity as an independent company to take even the balance sheet risk targeted by the current strategy (+100 MEUR investments).

If Taaleri decides to maintain its current structure, capital allocation remains the key question. The company's current strategy aims at significant bioindustry investments, but progress has been clearly slower than originally scheduled. The outlook for the bioindustry sector has also become clearly weaker than before due to, e.g., changes in regulation. We consider it very likely that the company will revise its strategy regarding bioindustry investments, and in our opinion, this would also be warranted.

If the company decides to continue with its current structure and wishes to continue its active investment operations (biotech or other targets), it should shift its investor communication focus from an industrial company more towards an investment company. The company could openly state that all parts are for sale when the price is right (as they have been throughout the company's history). In addition, the company could openly state that it is pursuing an active and opportunistic capital allocation, as it has done throughout history. We note that the company's track record in investments is very good, as also evidenced by the group's excellent 24% returns on equity over 10 and 5 years.

Valuation	<b>2025</b> e	2026e	<b>2027</b> e
Share price	7.20	7.20	7.20
Number of shares, millions	28.4	28.6	28.8
Market cap	204	206	207
EV	207	173	186
P/E (adj.)	17.7	7.9	8.7
P/E	17.7	7.9	8.7
P/B	1.0	0.9	0.9
P/S	3.8	3.2	3.2
EV/Sales	3.9	2.7	2.9
EV/EBITDA	10.2	5.0	5.8
EV/EBIT (adj.)	10.8	5.0	5.9
Payout ratio (%)	60.0 %	60.0 %	60.0 %
Dividend yield-%	3.4 %	7.6 %	6.9 %



### **High expectations for the CMD**

In this scenario, it would also be desirable for the company to clarify its dividend policy and indicate that it will distribute, in addition to the basic dividend, extra profit distribution when larger non-recurring fees materialize in the future. In the big picture, we believe that the more aggressive the company's profit-sharing is, the smaller the discount related to the sum of parts, as the value of the parts would start to be unlocked through profit-sharing.

If the company continues with a conglomerate structure, a discount to the sum of parts would be fully warranted (Taaleri's historical discount relative to the sum of parts of around 15-20%). However, by taking the investor story more towards an investment company, it would be possible to reduce the discount.

We also believe that the larger the role bioindustry investments play in the strategy, the larger the discount in the sum of the parts will be in the coming years. This is purely because the timelines for its balance sheet bioindustry investments are long, and the potential is not likely to be realized until the end of the decade.

As we stated above, we find it difficult to see the value inherent in Taaleri's parts being fully realized under the current structure. The group's most valuable part, Garantia, is inevitably relegated to a supporting role in the investor story, as the core lies in private equity funds. For the value to be fully realized under the current structure, the following would need to happen: improved earnings predictability, significant clarification of the strategy, confidence in bioindustry investments, and better visibility into the use of the balance sheet. We consider this unlikely to materialize.

#### How could the value be unlocked?

The most logical catalyst for materializing value would be for the company itself to decide to unlock the value


inherent in its parts. This would be relatively easy to implement, for example, through a spin-off or some other major arrangement. Another option for the company to unlock value would be a revision in the capital allocation strategy, by shifting the focus from balance sheet investments to profit-sharing.

We also note that a catalyst for value unlocking could also come from outside the company. In practice, this would mean that someone would make a sufficiently attractive offer for Energy or Garantia. We consider this unlikely for Garantia, but we see Energy as a very attractive acquisition target. We believe that Energy is attracting broad interest among companies in the sector, both in Finland and abroad.


We also note that the release of value through the implementation of the current strategy is also possible. At the core of this would be successful exits from Fintoil and Biocoal (building a track record) as well as subsequent investments in the sector. In addition, the release of capital from other investments would also help unlock value. However, even in the best-case scenario, this scenario would probably take years, and in this scenario, there would be a clear risk that the value of the parts would not be fully reflected due to the conglomerate structure.

Overall, we still assign over a 50% probability that the value of the company's parts will be unlocked within the next two years, and in this scenario, the share's annual return would be excellent. All eyes are firmly on the CMD to be held on September 2. If the company's message at the CMD is that it will continue with a slightly refined current strategy, the probability of value unlocking would decrease. Even in this scenario, however, we consider it realistic that the current historically large undervaluation relative to the sum-of-the-parts would close at least partially.

#### Discount/premium relative to the sum of the parts





### Share price and SOTP (Inderes estimate, EUR/share)




### **Valuation table**

Valuation	2020	2021	2022	2023	2024	<b>2025</b> e	<b>2026</b> e	2027e	<b>2028</b> e
Share price	8.12	11.5	12.8	8.99	8.03	7.20	7.20	7.20	7.20
Number of shares, millions	28.4	28.4	28.4	28.3	28.2	28.4	28.6	28.8	29.0
Market cap	230	326	363	254	226	204	206	207	209
EV	289	308	331	234	227	207	173	186	176
P/E (adj.)	11.5	15.4	17.6	11.1	8.1	17.7	7.9	8.7	8.4
P/E	11.5	2.4	17.6	11.1	8.1	17.7	7.9	8.7	8.4
P/B	1.7	1.4	1.8	1.2	1.1	1.0	0.9	0.9	0.9
P/S	2.7	4.7	5.7	3.9	3.1	3.8	3.2	3.2	3.1
EV/Sales	3.3	4.4	5.2	3.6	3.1	3.9	2.7	2.9	2.6
EV/EBITDA	10.7	2.1	11.6	7.2	5.8	10.2	5.0	5.8	5.2
EV/EBIT (adj.)	11.8	10.7	12.1	7.3	6.0	10.8	5.0	5.9	5.3
Payout ratio (%)	187.2 %	25.0 %	96.3 %	123.3 %	50.3 %	60.0 %	60.0 %	60.0 %	60.0 %
Dividend yield-%	16.3 %	10.4 %	5.5 %	11.1 %	6.2 %	3.4 %	7.6 %	6.9 %	7.2 %







### **Peer group valuation**

Peer group valuation Company	Market cap MEUR	EV MEUR	EV/ 2025e	EBIT 2026e	EV/EI 2025e	BITDA 2026e	EV 2025e	7/S 2026e	P 2025e	-	Dividend 2025e	yield-% 2026e	P/B 2025e
Aktia	735								8.7	9.2	8.3	8.9	1.0
Alexandria	109	104	8.4	7.6	7.2	6.5	2.0	1.8	11.7	10.7	8.2	8.6	3.2
CapMan	335	328	10.7	7.8	10.3	7.5	5.2	4.3	16.5	12.1	7.9	8.5	1.7
Evli	519	519	11.6	10.2	10.7	9.6	4.7	4.4	16.5	14.5	6.1	6.3	3.4
eQ	552	540	18.7	14.1	17.9	13.6	9.0	7.3	24.1	19.1	4.2	5.3	7.4
Titanium	63	51	9.0	8.9	8.0	8.1	2.6	2.5	13.7	13.2	7.1	7.5	4.0
United Bankers	199	184	12.4	10.0	10.6	8.9	3.4	3.1	17.9	14.6	6.3	6.6	3.3
Mandatum	3062	2648	13.9	16.1	13.9	16.1	15.9	16.9	20.1	20.6	16.4	12.3	2.9
Taaleri (Inderes)	204	207	10.8	5.0	10.2	5.0	3.9	2.7	17.7	7.9	3.4	7.6	1.0
Average			12.1	10.7	11.2	10.0	6.1	5.7	16.1	14.2	8.1	8.0	3.4
Median			11.6	10.0	10.6	8.9	4.7	4.3	16.5	13.9	7.5	8.0	3.2
Diff-% to median			-7%	-50%	-3%	-44%	-18%	-37%	7%	-43%	-55%	-5%	-69%

Source: Refinitiv / Inderes

### **Income statement**

Income statement	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25e	Q4'25e	2025e	2026e	2027e	2028e
Revenue	65.6	17.2	12.6	22.2	20.7	72.6	9.3	13.5	12.5	18.3	53.6	63.4	64.7	67.5
Private equity funds	42.3	6.5	6.8	6.6	9.5	29.4	6.5	8.9	7.2	8.6	31.2	38.1	34.5	36.6
Garantia	17.9	8.7	4.7	6.8	5.3	25.5	2.4	5.1	4.7	5.1	17.2	21.1	21.8	22.4
Others	6.1	0.9	0.6	0.3	0.2	2.0	0.3	0.2	0.4	0.4	1.3	1.5	1.5	1.5
EBITDA	32.4	9.8	4.6	14.9	9.6	39.0	0.7	4.9	5.2	9.5	20.2	34.8	31.9	33.6
Depreciation	-0.5	-0.2	-0.2	-0.2	-0.2	-0.9	-0.2	-0.4	-0.2	-0.2	-0.9	-0.3	-0.3	-0.3
EBIT (excl. NRI)	31.9	9.6	4.4	14.7	9.4	38.1	0.5	4.5	5.0	9.3	19.2	34.5	31.6	33.3
EBIT	31.9	9.6	4.4	14.7	9.4	38.1	0.5	4.5	5.0	9.3	19.2	34.5	31.6	33.3
Private equity funds	14.9	1.1	1.2	2.1	3.1	7.4	1.4	3.0	2.1	2.2	8.6	17.0	12.3	13.8
Garantia	16.5	8.5	4.7	6.3	4.8	24.3	2.1	5.0	4.4	4.8	16.3	20.0	20.6	21.1
Others	0.5	-0.9	-1.1	-1.5	-2.1	-5.7	-2.1	-1.9	-1.6	-1.9	-7.4	-6.9	-7.2	-7.5
Net financial items	-1.2	-0.2	-0.2	-0.2	-0.2	-0.9	-0.1	-0.1	-0.1	-0.1	-0.4	-0.3	-0.3	-0.3
PTP	30.7	9.4	4.2	14.5	9.1	37.1	0.4	4.4	4.9	9.2	18.9	34.2	31.3	33.0
Taxes	-4.2	-1.9	-0.8	-1.4	-0.7	-4.7	0.4	-2.3	-1.0	-1.9	-4.9	-6.8	-5.8	-6.1
Minority interest	-3.6	-0.1	-0.3	-2.2	-1.8	-4.4	-0.2	-0.2	-1.0	-1.0	-2.4	-1.4	-1.8	-1.9
Net earnings	22.9	7.4	3.1	11.0	6.6	28.0	0.6	1.9	2.9	6.2	11.6	25.9	23.7	25.0
EPS (adj.)	0.81	0.26	0.11	0.39	0.23	0.99	0.02	0.07	0.10	0.22	0.41	0.91	0.82	0.86
EPS (rep.)	0.81	0.26	0.11	0.39	0.23	0.99	0.02	0.07	0.10	0.22	0.41	0.91	0.82	0.86
Key figures	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25e	Q4'25e	2025e	2026e	<b>2027</b> e	2028e
Revenue growth-%	3.8 %	69.1 %	-46.9 %	64.7 %	13.4 %	10.6 %	-45.7 %	6.6 %	-43.4 %	-11.3 %	-26.1 %	18.1 %	2.1 %	4.3 %
Adjusted EBIT growth-%	16.5 %	515.7 %	-75.2 %	156.3 %	36.3 %	19.4 %	-94.9 %	2.7 %	-66.1 %	-1.3 %	-49.5 %	79.5 %	-8.4 %	5.3 %
EBITDA-%	49.3 %	57.3 %	36.2 %	67.5 %	46.5 %	53.6 %	7.0 %	36.2 %	41.4 %	51.6 %	37.6 %	54.9 %	49.3 %	49.8 %
Adjusted EBIT-%	48.6 %	55.9 %	34.7 %	66.4 %	45.4 %	52.4 %	5.2 %	33.4 %	39.8 %	50.5 %	35.9 %	54.5 %	48.9 %	49.3 %
Net earnings-%	35.0 %	43.0 %	24.4 %	49.4 %	32.0 %	38.6 %	6.2 %	14.0 %	22.8 %	34.0 %	21.5 %	40.9 %	36.7 %	37.0 %

Source: Inderes

Full-year EPS is calculated using the number of shares at the end of the year.

### **Balance sheet**

Assets	2023	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e
Non-current assets	221	224	227	234	255
Goodwill	0.3	0.3	0.3	0.3	0.3
Intangible assets	0.2	0.2	0.2	0.2	0.2
Tangible assets	2.4	1.8	1.3	1.4	1.6
Associated companies	51.6	55.4	59.3	66.0	87.0
Other investments	161	159	159	159	159
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	5.1	7.6	7.6	7.6	7.6
Current assets	87.3	67.9	64.4	78.0	66.8
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	17.2	9.3	9.3	9.3	9.3
Receivables	31.8	39.0	37.6	15.8	16.2
Cash and equivalents	38.3	19.6	17.6	52.9	41.3
Balance sheet total	308	292	292	312	322

Liabilities & equity	2023	2024	2025e	<b>2026</b> e	2027e
Equity	209	215	215	236	246
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	187	190	187	206	214
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	18.8	18.8	18.8	18.8	18.8
Other equity	0.0	0.0	0.0	0.0	0.0
Minorities	2.5	6.6	9.0	10.4	12.2
Non-current liabilities	77.8	55.9	55.9	55.9	55.9
Deferred tax liabilities	16.5	12.3	12.3	12.3	12.3
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	14.9	0.0	0.0	0.0	0.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	46.4	43.6	43.6	43.6	43.6
Current liabilities	21.5	20.7	20.7	20.7	20.7
Interest bearing debt	0.0	0.0	0.0	0.0	0.0
Payables	0.0	0.0	0.0	0.0	0.0
Other current liabilities	21.5	20.7	20.7	20.7	20.7
Balance sheet total	308	292	292	312	322

### **DCF-calculation**

DCF model	2024	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e	<b>2028</b> e	<b>2029</b> e	2030e	<b>2031</b> e	<b>2032</b> e	<b>2033</b> e	2034e	TERM
Revenue growth-%	10.6 %	-26.1 %	18.1 %	2.1 %	4.3 %	3.0 %	3.0 %	3.0 %	2.5 %	2.5 %	2.5 %	2.5 %
EBIT-%	52.4 %	35.9 %	54.5 %	48.9 %	49.3 %	47.0 %	46.0 %	45.0 %	45.0 %	45.0 %	45.0 %	45.0 %
EBIT (operating profit)	38.1	19.2	34.5	31.6	33.3	32.7	32.9	33.2	34.0	34.9	35.7	
+ Depreciation	0.9	0.9	0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.5	0.6	
- Paid taxes	-11.4	-4.9	-6.8	-5.8	-6.1	-6.0	-6.0	-6.1	-6.2	-6.4	-6.6	
- Tax, financial expenses	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	-0.1	1.4	21.7	-0.3	-0.7	-0.5	-0.5	-0.5	-0.5	-0.5	-0.5	
Operating cash flow	27.3	16.6	49.6	25.7	26.8	26.5	26.7	27.0	27.8	28.5	29.2	
+ Change in other long-term liabilities	-2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	2.1	-0.4	-0.4	-0.5	-0.5	-0.6	-0.6	-0.7	-0.7	-0.8	-0.8	
Free operating cash flow	26.5	16.3	49.2	25.3	26.3	25.9	26.1	26.3	27.0	27.7	28.5	
+/- Other	-3.8	-3.9	-6.7	-21.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	22.7	12.3	42.5	4.3	26.3	25.9	26.1	26.3	27.0	27.7	28.5	387
Discounted FCFF		11.9	37.2	3.4	19.0	17.0	15.6	14.3	13.3	12.4	11.6	158
Sum of FCFF present value		314	302	265	261	242	225	209	195	182	169	158
Enterprise value DCF		314										

0.0

19.6

-20.0

-14.1

299

10.5

### **Cash flow distribution**



#### WACC

-Minorities

- Interest bearing debt


-Dividend/capital return

**Equity value DCF** 

+ Cash and cash equivalents

**Equity value DCF per share** 


Weighted average cost of capital (WACC)	10.0 %
Cost of equity	10.0 %
Risk free interest rate	2.5 %
Liquidity premium	1.00%
Market risk premium	4.75%
Equity Beta	1.38
Cost of debt	5.0 %
Target debt ratio (D/(D+E)	0.0 %
Tax-% (WACC)	20.0 %
WACC	




■2025e-2029e ■2030e-2034e ■TERM

### DCF sensitivity calculations and key assumptions in graphs







#### Sensitivity of DCF to changes in the terminal EBIT margin



#### Sensitivity of DCF to changes in the risk-free rate



#### Growth and profitability assumptions in the DCF calculation



### **Summary**

Income statement	2022	2023	2024	2025e	<b>2026</b> e	Per share data	2022	2023	2024	<b>2025</b> e	<b>2026e</b>
Revenue	63.2	65.6	72.6	53.6	63.4	EPS (reported)	0.73	0.81	0.99	0.41	0.91
EBITDA	28.6	32.4	39.0	20.2	34.8	EPS (adj.)	0.73	0.81	0.99	0.41	0.91
EBIT	27.4	31.9	38.1	19.2	34.5	OCF / share	0.58	0.06	0.97	0.59	1.73
РТР	26.4	30.7	37.1	18.9	34.2	FCF / share	2.04	0.22	0.81	0.43	1.49
Net Income	20.6	22.9	28.0	11.6	25.9	Book value / share	7.16	7.28	7.40	7.26	7.88
Extraordinary items	0.0	0.0	0.0	0.0	0.0	Dividend / share	0.70	1.00	0.50	0.24	0.54
Balance sheet	2022	2023	2024	<b>2025</b> e	<b>2026</b> e	Growth and profitability	2022	2023	2024	<b>2025</b> e	<b>2026</b> e
Balance sheet total	300.8	307.9	291.9	291.7	312.2	Revenue growth-%	-9%	4%	11%	-26%	18%
Equity capital	202.7	208.7	215.3	215.2	235.6	EBITDA growth-%	-80%	13%	20%	-48%	<b>72</b> %
Goodwill	0.3	0.3	0.3	0.3	0.3	EBIT (adj.) growth-%	-5%	16%	19%	-49%	80%
Net debt	-31.9	-23.4	-19.6	-17.6	-52.9	EPS (adj.) growth-%	-2%	11%	23%	-59%	123%
						EBITDA-%	45.2 %	49.3 %	53.6 %	37.6 %	54.9 %
Cash flow	2022	2023	2024	<b>2025</b> e	2026e	EBIT (adj.)-%	43.3 %	48.6 %	52.4 %	35.9 %	54.5 %
EBITDA	28.6	32.4	39.0	20.2	34.8	EBIT-%	43.3 %	48.6 %	52.4 %	35.9 %	54.5 %
Change in working capital	-6.8	-23.5	-0.1	1.4	21.7	ROE-%	9.5 %	11.2 %	13.5 %	5.6 %	12.0 %
Operating cash flow	16.5	1.6	27.3	16.6	49.6	ROI-%	11.8 %	14.5 %	17.3 %	8.9 %	15.3 %
CAPEX	15.0	-9.7	2.1	-0.4	-0.4	Equity ratio	67.4 %	67.8 %	73.8 %	73.8 %	<b>75.5</b> %
Free cash flow	57.7	6.2	22.7	12.3	42.5	Gearing	-15.8 %	-11.2 %	-9.1 %	-8.2 %	<b>-22.4</b> %
Valuation multiples	2022	2023	2024	2025e	2026e						
EV/S	5.2	3.6	3.1	3.9	2.7						
EV/EBITDA	11.6	7.2	5.8	10.2	5.0						
EV/EBIT (adj.)	12.1	7.3	6.0	10.8	5.0						
P/E (adj.)	17.6	11.1	8.1	17.7	7.9						

**Dividend-%**Source: Inderes

1.8

5.5 %

1.2

11.1 %

P/B

1.0

3.4 %

0.9

7.6 %

1.1

6.2 %

### Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of
	the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of

the share is weak

Sell The 12-month risk-adjusted expected shareholder return of

the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.


Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

#### Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
5/10/2021	Accumulate	11.50 €	10.65€
5/24/2021	Accumulate	12.50 €	11.65 €
6/1/2021	Accumulate	11.50 €	11.20 €
8/20/2021	Accumulate	11.50 €	10.85€
11/8/2021	Accumulate	11.50 €	10.95 €
12/2/2021	Reduce	11.50 €	11.50 €
2/17/2022	Reduce	12.00€	11.80 €
5/2/2022	Reduce	11.00€	10.38€
5/9/2022	Accumulate	11.00€	9.92 €
8/22/2022	Accumulate	11.00€	10.16 €
10/31/2022	Accumulate	11.00€	9.35€
11/7/2022	Accumulate	11.00€	9.91 €
2/7/2023	Sell	11.00€	12.82 €
2/17/2023	Reduce	11.00€	11.34 €
4/17/2023	Reduce	11.00€	10.42€
5/4/2023	Reduce	11.00€	10.40 €
8/14/2023	Accumulate	11.00€	9.42 €
8/17/2023	Accumulate	11.00€	9.65€
11/2/2023	Accumulate	10.00€	8.50 €
11/30/2023	Accumulate	10.00€	8.63€
2/12/2024	Accumulate	10.00€	9.16 €
2/15/2024	Reduce	10.00€	9.70 €
5/8/2024	Reduce	9.50€	8.70 €
8/21/2024	Accumulate	9.50€	8.34 €
11/6/2024	Accumulate	9.50€	8.18 €
1/17/2025	Accumulate	9.00€	7.72 €
2/13/2025	Accumulate	9.00€	7.97€
4/8/2025	Buy	9.00€	6.40€
4/30/2025	Buy	9.00€	7.12 €
8/14/2025	Buy	9.00€	7.20 €



# CONNECTING INVESTORS AND COMPANIES.

Inderes connects investors and listed companies.

We serve over 400 Nordic listed companies that want to better serve investors. The Inderes community is home to over 70,000 active investors.

We provide listed companies with solutions that enable seamless and effective investor relations. The Inderes service is built on four cornerstones for high-quality investor relations: Equity Research, Events, IR Software, and Annual General Meetings (AGM).

Inderes operates in Finland, Sweden, Norway, and Denmark and is listed on the Nasdaq First North Growth Market.

Inderes was created by investors, for investors.

Inderes Ab

Vattugatan 17, 5tr Stockholm

+46 8 411 43 80

inderes.se

**Inderes Oyj** 

Porkkalankatu 5 00180 Helsinki

+358 10 219 4690

inderes.fi

